Table 1 Baseline Factors for Patients Initiating HAART in the Natural History Study
Characteristic | Total (n = 2327) | Early Initiation Era (n = 1631) | Late Initiation Era (n = 696) | P valueb |
|---|---|---|---|---|
Demographics | Â | Â | Â | Â |
   Age at HIV Diagnosis, years | 30.1 ± 8.1 | 29.8 ± 7.9 | 30.8 ± 8.6 | 0.007 |
   Age at HAART initiation, years | 34.7 ± 8.6 | 35.0 ± 8.2 | 34.1 ± 9.5 | 0.025 |
   Female | 221 (9.5%) | 169 (10.4%) | 52 (7.5%) | 0.029 |
   Race/ethnicity |  |  |  | 0.188 |
European American | 1024 (44.0%) | 730 (44.8%) | 294 (42.2%) | Â |
African American | 1021 (43.9%) | 717 (44.0%) | 304 (43.7%) | Â |
Hispanic | 194 (8.3%) | 130 (8.0%) | 64 (9.2%) | Â |
Other | 88 (3.8%) | 54 (3.3%) | 34 (4.9%) | Â |
   Rank of Officer/Warrant at study enrollment | 213 (9.9%) | 143 (9.4%) | 70 (10.1%) | 0.606 |
   Active Duty at HAART initiation | 1293 (55.6%) | 773 (47.4%) | 520 (74.7%) | <0.001 |
Medical History (prior to HAART Initiation) | Â | Â | Â | Â |
   Year of HIV Diagnosis | 1994 ± 5.9 | 1992 ± 4.2 | 2000 ± 5.1 | <0.001 |
   HIV Diagnosis to HAART initiation, months | 44.2 (5.7 - 95.2) | 60.9 (16.9 - 103.8) | 10.1 (2.0 - 45.5) | <0.001 |
   Nadir CD4+ to HAART initiation, months | 3.3 (0.4 - 16.3) | 6.5 (0.7 - 19.4) | 0.8 (0.2 - 3.7) | <0.001 |
   Seroconverters (SC)a | 1691 (72.7%) | 1106 (67.8%) | 585 (84.1%) | <0.001 |
   Estimated date of SC to HIV Diagnosis, months | 8.1 (5.0 - 13.7) | 8.4 (5.3 - 14.4) | 7.4 (5.0 - 13.7) | 0.010 |
   Viral Load at HAART initiation, log10 copies/mL | 4.3 ± 1.0 | 4.3 ± 1.0 | 4.4 ± 0.9 | <0.001 |
   CD4+ at HIV Diagnosis, cells/mL | 499.7 ± 248.0 | 524.0 ± 252.1 | 448.0 ± 231.0 | <0.001 |
   CD4+ nadir, cells/mL | 283.2 ± 174.0 | 276.4 ± 183.3 | 299.6 ± 148.1 | 0.005 |
   CD4+ at HAART Initiation, cells/mL | 342.8 ± 211.6 | 341.0 ± 223.4 | 346.6 ± 184.8 | 0.590 |
<200 | 459 (24.4%) | 357 (28.0%) | 102 (16.7%) | <0.001 |
200-349 | 581 (30.8%) | 331 (26.0%) | 250 (40.9%) | Â |
350+ | 845 (44.8%) | 586 (46.0%) | 259 (42.4%) | Â |
   Prior AIDS-Defining Event | 277 (11.9%) | 231 (14.2%) | 46 (6.6%) | <0.001 |
   Chronic Hepatitis B co-infection | 128 (6.1%) | 110 (7.4%) | 18 (2.9%) | <0.001 |
   Hepatitis C co-infection | 121 (6.1%) | 99 (7.1%) | 22 (3.6%) | 0.002 |
   Prior Sexually Transmitted Infections (STI) | 1058 (45.5%) | 839 (51.4%) | 219 (31.5%) | <0.001 |
   ARV Use (mono- or dual-therapy) | 1224 (52.6%) | 1121 (68.7%) | 103 (14.8%) | <0.001 |
   Hemoglobin, g/dL | 14.1 ± 1.6 | 13.9 ± 1.6 | 14.4 ± 1.4 | <0.001 |
   ALT, μ/L | 47.1 ± 53.7 | 48.2 ± 52.9 | 45.1 ± 55.2 | 0.336 |
   Creatinine, mg/dL | 1.0 ± 0.2 | 1.0 ± 0.2 | 1.0 ± 0.2 | <0.001 |
Initial HAART Regimen | Â | Â | Â | Â |
   Unboosted PI | 1320 (56.7%) | 1261 (77.3%) | 59 (8.5%) | <0.001 |
   Boosted PI | 205 (8.8%) | 121 (7.4%) | 84 (12.1%) |  |
   NNRTI | 622 (26.7%) | 169 (10.4%) | 453 (65.1%) |  |
   PI + NNRTI + NRTI | 86 (3.7%) | 71 (4.4%) | 15 (2.2%) |  |
   3 NRTI | 94 (4.0%) | 9 (0.6%) | 85 (12.2%) |  |